Technology | April 14, 2010

Linear Accelerator’s Motion Control Solution Helps Target Tumors

April 14, 2010 - One of the biggest challenges in radiation therapy is delivering the dose without damaging surrounding healthy tissue. This is particularly difficult with tumors that move due to patient respiration. A new motion management system is designed to monitor and adjust for tumor motion during standard treatment and respiratory gating treatment.
Varian Medical Systems has added advanced motion management capabilities, including gated RapidArc, to its Trilogy platform for treating cancer with targeted radiotherapy. A new set of tools enables clinicians to monitor and adjust for tumor motion during treatment, and to utilize respiratory gating during a RapidArc treatment.
Gated RapidArc radiotherapy makes it possible to monitor patient breathing and compensate for tumor motion, while delivering dose during a continuous rotation around the patient. This is designed to enable targeting lung tumors with greater precision by gating the beam — turning it on and off — in response to tumor motion.
The new Trilogy system also incorporates an open interface that can be used with positioning devices like the Calypso System, allowing clinicians to monitor tumors in real time, gate the beam if the tumor moves outside of a predefined area, and make targeting adjustments when necessary.
The motion management interface can also be used with surface imaging technologies from Vision RT and other providers to position the patient, to monitor continuously for any movement, and to gate the treatment beam either as a result of detected patient motion or according to the patient's breathing cycle.
The interface also opens the door for other third party companies to connect their devices to Varian accelerators for the purpose of monitoring motion. These capabilities can be applied during frameless radiosurgery and stereotactic body radiation therapy (SBRT).
For more information: www.varian.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...